New indications, oral GLP-1s, cash pay, and new fulfillment models are making these medications more accessible than everand fueling increased utilization and costs
[] In the SUSTAIN 6 trial, semaglutide reduced the risk of new or worsening nephropathy, showing an HR of 0.64 (95% CI: 0.460.88
Our findings show that liraglutide may be effective in the treatment of unresponsive high-frequency or chronic migraine in patients with obesity, the researchers, based at the University of Naples Federico II, wrote in their paper, published this month in the journal Headache
The smarter strategy: Combine low-dose GLP-1s with human-led coaching At Embla, we believe medication should support weight loss not carry it alone
Gaytan et al., 2005
Neither form is FDA approved